Clear Street on Enliven Therapeutics (ELVN): MRK's TERN acquisition 'sharpens investment case for ELVN-001'

March 25, 2026 10:04 AM

Clear Street analyst Kaveri Pohlman reiterated a Buy rating and $36.00 price target on Enliven Therapeutics (NASDAQ: ELVN)The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found